Özet:
Abstract:Background/Aims: Lipoxin A4 (LXA4), an anti-inflammatory lipid mediator, regulates leukocyte cellular activity and activates genetranscription. The therapeutic effect of LXA4 on liver fibrosis and its mechanism on the immune system are largely unknown. Becausethe regenerative capacity of hepatocytes in acute and chronic liver failure models of mouse increases by silencing MKK4, we aimed toinvestigate the effect of parenteral administration of LXA4 on the genes responsible for regeneration of liver, namely MKK4, MKK7, andATF2, and visualize the therapeutic effects in an experimental model.Materials and Methods: Fibrosis was induced in mice by administration of thioacetamide (TAA). LXA4 was administered during the lasttwo weeks of fibrosis induction. The fibrosis level was measured by Knodell scoring. The liver function was measured by analyzing serumALT, AST, and AP levels. Expression levels of genes responsible for liver fibrosis (TGF-α) and cell regeneration (MKK4, MKK7, and ATF2)have been measured by RT-PCR analysis. Inflammatory and anti-inflammatory cytokine levels were measured in serum samples andliver homogenates by Enzyme Linked Immunosorbent Assay (ELISA). Ultrathin sections were examined using a transmission electronmicroscope and analyzed.Results: We observed significant healing in liver of the LXA4-treated group, histologically. This finding was in parallel with reduction ofserum ALT, AST, but not AP levels. TGF-α and MKK4 expressions were significantly reduced in the LXA4-treated group. Administrationof LXA4 caused significant elevation of IL-10 in systemic circulation; however, that elevation was not detected in liver homogenates.Nevertheless, significant reductions in TNF-α and IL-17 have been observed.Conclusion: The anti-inflammatory effect of LXA4 maintains the regenerative capacity of liver during fibrosis in an experimental liverfibrosis model. LXA4 may be therapeutically beneficial in liver fibrosis.
